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The development of a wide array of molecular and neuroscientific biomarkers can provide
the possibility to visualize the course of Alzheimer’s disease (AD) at early stages.
Many of these biomarkers are aimed at detecting not only a preclinical, but also a
pre-symptomatic state. They are supposed to facilitate clinical trials aiming at treatments
that attack the disease at its earliest stage or even prevent it. The increasing number
of such biomarkers currently tested and now partly proposed for clinical implementation
calls for critical reflection on their aims, social benefits, and risks. This position paper
summarizes major challenges and responsibilities. Its focus is on the ethical and social
problems involved in the organization and application of dementia research, as well as in
healthcare provision from a cross-national point of view. The paper is based on a discussion
of leading dementia experts from neuroscience, neurology, social sciences, and bioethics
in the United States and Europe. It thus reflects a notable consensus across various
disciplines and national backgrounds. We intend to initiate a debate on the need for actions
within the researchers’ national and international communities.
Keywords: late-onset Alzheimer’s dementia, medical ethics, recommendations, biomarker, public health policy,
research participation, cultural diversity, public engagement
INTRODUCTION
Alzheimer’s disease (AD) is a substantial individual threat and
a major public-health challenge (WHO, 2012). Until now, there
is no preventive measure or curative therapy for late-onset
AD (LOAD), and symptom relief is limited (Daviglus et al.,
2010). New research approaches aim at delaying onset of LOAD
through treatment of “at-risk individuals”. This mirrors a general
shift from pathological diagnosis to assessment of risk factors:
Prediction and the start of treatment are now considered plausible
approaches at the pre-symptomatic phase (Sperling et al., 2011,
2013; Shim and Morris, 2011).
Biomarkers for the identification of at-risk healthy individuals
include genetic testing of APOE ε4 (Keage et al., 2010) as well
as vascular risk factors (Kivipelto et al., 2005). Neurological
biomarkers comprise positron emission tomography (PET)
measures of beta-amyloid plaques (Aβ) (Nordberg et al.,
2013), cerebrospinal fluid (CSF levels of Aβ and of total-and
phosphorylated-tau) (Visser et al., 2009; Landau and Frosch,
2014), functional and structural magnetic resonance imaging
(MRI), e.g., hippocampal volume (Filippi et al., 2012), and
biomarkers reflecting metabolic or inflammatory changes
associated with LOAD (Mapstone et al., 2014). Several of these
biomarkers might predict LOAD even at the mild cognitive
impairment (MCI) (Petrella et al., 2011; Prestia et al., 2013) or
pre-MCI stage (Parra et al., 2010). Since some examinations are
invasive, time-consuming, expensive, or ethically problematic,
neuro-psychological and cognitive tests (e.g., MiniMental-State
(MMSE)) (Jessen et al., 2011; Palmqvist et al., 2012) or blood
tests (Mapstone et al., 2014) are also explored as low-cost-low-
risk tests for potential public screening. The likely dynamic of
different biomarkers during the pathophysiological process of
LOAD is a major challenge (Jack et al., 2013) and still requires
extensive validation of the various markers (Albert et al., 2011).
In summary, the stages discussed include a long asymptomatic
stage where healthy or minimally symptomatic individuals have
different (genetic, physiological, or molecular) risk factors,
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followed by a pre-dementia stage with mild symptoms that can
be differentiated into subjective cognitive impairment (SCI) or
MCI, and, finally, a symptomatic clinical dementia stage. For
each of these different stages, biomarkers like the ones mentioned
above are being explored and need to be validated in view of their
use for dementia prevention. Three major levels are distinguished
that parallel the three stages of disease development (Wright
et al., 2009; Kryscio, 2014): Primary prevention addresses the
healthy public; secondary prevention aims at early detection of
disease by screening biomarkers to apply treatment that can stop
progression. Tertiary prevention follows the clinical diagnosis with
the aim of slowing down progression or reducing complications.
The biomarkers as well as the diagnosis of the prodromal stage
need to be validated, reproduced, standardized, and tested for
predictive value in longitudinal studies. However, the potential
for biomarkers to identify individuals who are asymptomatic and
could benefit from therapies (not yet available) has revolutionized
thinking about the approach to dementia care and changed the
landscape of clinical trials for dementia.
This trend towards pre-symptomatic prediction has recently
evoked strong ethical and sociological criticism (Le Couteur et al.,
2013; Lock, 2013). Thus, David Le Couteur and his colleagues
argue that it will mainly lead to overdiagnosis of AD and will
therefore rather harm people. It is important to note that the
development of biomarkers for LOAD occurs in an environment
that, so far, largely lacks systematic ethical reflection. There is
not even a specific ethical framework that could help politi-
cians, public health decision makers, healthcare professionals,
and families to deal with people at risk for developing dementia.
Since biomarker research for dementia is still in its infancy,
this is a critical point in time for developing an appropriate
ethical framework in view of current research and future clinical
implementation. The potential of current biomarker research
to challenge understandings and clinical practices regarding
LOAD should not be underestimated (Waldemar et al., 2007).
In addition to the above mentioned future aim of primary,
secondary, and tertiary prevention, some biomarkers have been
approved by regulatory agencies and are, at least theoretically,
available for clinical application. Such biomarkers could the-
oretically be used for predictive and screening purposes. This
could occur if patients request these tests or if these tests were
publicly promoted, e.g., as part of a so-called national dementia
strategy.
Important questions that have not found sufficient considera-
tion, so far, are related to the value and risk of knowing for differ-
ent actors such as potentially affected persons, their families, the
medical profession, and the various national healthcare systems
(Karlawish, 2011). Furthermore, the current scholarly debate has
to expand its scope beyond the setting of Western, industrialized
countries. While healthcare policies and legal frameworks are
contextualized in national settings, the research community is
increasingly globalized. The resulting tensions have not received
sufficient consideration, so far. They pose new problems and
emphasize our responsibility as professionals and scientists to act
as mediators between local contexts and global developments.
The following interdisciplinary considerations identify four
different ethical and social dimensions, thus systematizing the
current debate around central problems, controversies, and open
questions in order to promote future research initiatives and
open a more cross-cultural perspective: 1. healthcare and research
policy balancing between research for early diagnosis and care
provision for existing patients, 2. ethical issues related to partic-
ipation in dementia research and disclosure of information on
pre-dementia stages such as MCI, 3. long-term implications of
dealing with predictive information on a personal and social level
in different cultures and healthcare systems, and 4. enhancing the
dialog between scientists, the public, and persons being directly
affected.
PUBLIC POLICY GOALS AND CONCERNS
RATIONALE
Late-onset AD has become the target of many national action
plans worldwide, e.g., in Australia, France, the Netherlands, Nor-
way, and England. The challenge of the research lies in the com-
plexity of progressive, multi-dimensional dementing syndromes:
First, the aging brain can show multiple forms of pathological
change causing dementia progression. Second, even in LOAD,
different neuropathological factors, such as amyloid plaques, neu-
rofibrillary tangles, and synaptic alterations, have been identified,
but the contribution of each to the clinical picture is controversial.
Third, LOAD often shows mixed etiology with vascular diseases.
Finally, relationships between the genetic and neuronal level on
the one hand and the cognitive and behavioral level on the other
have not been established.
A variety of approaches are employed to diagnose LOAD
(Waldemar et al., 2007). Genetic ApoE-tests are not recom-
mended due to their low predictive value (Goldman et al., 2011).
The major paradigm shift is to identify brain changes as biomark-
ers for predicting cognitive decline at preclinical stages (Albert
et al., 2011; Hampel et al., 2014). Even among AD researchers,
the concept of pre-symptomatic AD is being debated and requires
validation. Although methods of neuroimaging to detect disease
specific pathological brain changes might offer better prediction
than genetic testing, they also raise important public health con-
cerns regarding resource allocation.
RECOMMENDATIONS
In the framework of democratic regulation of research and
healthcare, shifts in agenda and priority setting require public
information and debate. If early diagnosis is to be clinically
employed, there is a need to validate the biomarkers and
to identify possible co-factors explaining variation between
pathological and symptomatic levels. However, an exclusive
focus of public policy in dementia research on early detec-
tion raises concerns. First, it is not clear whether efficient
treatment with acceptable side-effects will be available in the
immediate future. It is an ethical requirement to avoid pre-
mature success reports and ill-founded claims that may under-
mine the legitimacy of biomedical research. Second, scientific
and public policy communities should be transparent regard-
ing uncertainties and potential financial and social costs of
early diagnosis and treatments in order to foster informed
public deliberation and adequate consideration of benefits and
concerns.
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KEY QUESTIONS FOR FURTHER DEBATES AND RESEARCH
• Is there a socially accepted wish to know or share knowledge
about dementia predisposition? Is there social and cultural
diversity about this?
• Given the heterogeneous structure of public healthcare in var-
ious countries, what is the overarching professional respon-
sibility in organizing a transnational strategy for care and
prevention of dementia?
• What is the responsibility of a nation to promote primary
prevention of dementia targeting the healthy population,
especially if evidence for effectiveness remains uncertain?
ETHICAL ISSUES OF RESEARCH PARTICIPATION
RATIONALE
Research into LOAD depends on the participation of large
numbers of affected persons at different stages of neuronal
decline. Informed consent is considered a necessary precondition.
It includes sufficient information, assessment of capacity and
understanding, as well as voluntary authorization (Appelbaum,
2007). Since affected persons display different levels of capacity,
their involvement poses a range of ethical problems (Kim et al.,
2011).
Pre-symptomatic persons are usually considered competent.
However, they will often not be aware of being in an “at-risk
state”. Therefore, their identification as research subjects cannot
rely solely on self-recruitment, but requires antecedent measures.
As a result, persons might be confronted with information causing
psychological distress, posing difficult questions of disclosure,
and leading to social stigmatization (Illes et al., 2007). Out of
fear, pre-symptomatic persons may also be more vulnerable to
therapeutic misconception (Fisher et al., 2012) and might falsely
expect a therapeutic benefit of biomarker research. Research
subjects should understand the difference between biomarker
research and clinical trials. Of course, the value of participating in
biomarker research may change over time from primarily altru-
istic to more personal benefit, as standardization and knowledge
improve.
Involving persons with early stages of LOAD is important
for investigating the standard course of disease and testing the
predictive value of biomarkers as well as the efficacy of new
therapeutic approaches. However, including these persons poses
the problem of assessing decision-making capacity. Depending
on type and stage of dementia, this capacity may not be stable
but rather fluctuating, and usually declines over time (Karlawish,
2003; Kim et al., 2011). Finally, the assessment of capacity
depends on emotional factors, interests, and expectations, and
varies between socio-cultural contexts. It requires not only
understanding risks and benefits, but also appreciating how
research participation will affect one’s own life. People with early
LOAD may have deficits that could make it difficult to meet this
criterion (Karlawish, 2003).
Involving persons in advanced stages of LOAD poses the prob-
lems of research with incompetent subjects. Higher safeguards
such as minimal-risk conditions and alternative procedures to
protect personal integrity and best interest are applied, espe-
cially in potentially non-therapeutic research. Notably, there is no
international consensus on the definition of minimal-risk condi-
tions and the acceptability of proxy decisions (Kopelman, 2004).
RECOMMENDATIONS
Furthering research constitutes an honorable objective. How-
ever, there are still substantial national differences regarding
the development and implementation of ethical guidelines
for research with cognitively impaired participants (American
College of Physicians, 1989; Council of Europe, 1997; National
Bioethics Advisory Commission, 1998). Regardless of the national
research setting, the different stages of the potential subjects’
LOAD have to be taken into account. As affected persons’ capacity
to consent can change over time, it has to be re-evaluated on
a regular basis to decide which informed consent conditions
apply.
Studies involving pre-symptomatic persons have to observe
high standards when dealing with potentially problematic pre-
dictive and diagnostic information. Special attention should be
paid to questions of disclosing, storing, and passing on this
information. Suitable measures should be taken to minimize
the risks of psychological distress, familial issues, and social
discrimination.
Studies addressing persons with early stages of dementia will
include many individuals who are clearly capable of providing
informed consent and there are existing methods for assessing
this and documenting it (Marson et al., 1995). Such methods
should be sensitive to cultural differences. Instead of general-
izing incapacity of affected persons, supportive tools should be
implemented in unclear cases to maintain or enhance decision-
making capacity. The informed consent procedure should meet
requirements such as use of simple language, repetition of expla-
nation, rehearsals by affected persons and family members, and
visual presentations for increasing the understanding of risks and
benefits. Furthermore, family members can function as mediators
(not as legal proxies) where this is suitable to increase the affected
persons’ capacity. Continuing supervision and re-assessment of
decision-making capacity appears advisable to detect episodic
variation and long-term decline.
Studies involving persons with advanced forms of LOAD have
to protect the personal integrity and best interest of incompetent
subjects. They require careful assessment of risks and benefits
to meet minimal risk conditions for non-therapeutic research.
Proxy decision-making can involve ethical problems regarding
authorization, presumed will, and psychological burden. Alter-
natively, research advance directives allow the determination of
a person’s will with regard to research participation in the case
of cognitive incapacity. This necessitates sufficient deliberation
and consultations with trained professionals to avoid misunder-
standings, as well as a professional and legal framework that
ensures adherence. Also, opt-out models should be clarified.
Manifestations of assent, continuing self-identity, and “natural
will” should be taken into account (Karlawish, 2003; Kim et al.,
2011).
LOAD research also offers an opportunity to explore new,
innovative models of informed consent. Thus, the realiza-
tion of a model of “gradual informed consent transfer” could
emphasize the development of sustained relationships among
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subjects/patients, physicians and caregivers, and (an)other sig-
nificant person(s)/proxy medical decision maker(s). This allows
for gradual transfer of consent-giving capacity from the research
subject to accompanying others, e.g., during a longitudinal
study, and makes it more likely that these “companion proxies”
will know and implement the subject’s wishes (Overton et al.,
2013).
KEY QUESTIONS FOR FURTHER DEBATES AND RESEARCH
• How can we detect and overcome potential loopholes such
as therapeutic misunderstanding in existing informed consent
practices given a high risk of fear and psychological distress in
connection with a diagnosis of (pre-)dementia?
• Given the complexity of information on biomarkers and
dementia, how can subjects’ understanding of information
regarding research, diagnostics, and treatment be improved?
• How can we overcome a narrow focus on individual autonomy
and consider ethically and legally the role of the family and the
social practice of knowledge-sharing in pre-dementia research?
INDIVIDUAL AND SOCIAL CONSEQUENCES
RATIONALE
Predictive and diagnostic information on LOAD can open possi-
bilities of adapting life plans and making provisions. It may also
provide psychological relief and social exoneration. On the other
hand, it can pose difficult ethical problems:
On the individual level, this information can lead to
psychological distress and irreversible decisions, even up to
pre-emptive suicide, particularly when no efficacious therapies
are available. It can affect persons’ perceptions of themselves
and their families, leading to negative self-images. The REVEAL-
study on ApoE-genetic testing actually suggests that impacts
might be less severe (Green et al., 2009). However, some
studies indicate that lay people consider genetic information
as less decisive than, e.g., family history (Chilibeck et al.,
2011). Others point at considerable cultural or even national
differences regarding peoples’ interests to pursue genetic risk
assessment for AD (Alzheimer Europe, 2011). Similar studies
for neuro-biomarkers are needed to assess whether genetic and
neuroscientific information differ from a lay person’s perspective.
If the predictive value of biomarkers is better than ApoE-genetic
tests, their individual and social implications might differ.
In the family context, prognostic information can cause seri-
ous disruptions, especially when inheritable risk-factors may be
involved. This poses the question of who else might be concerned,
directly or indirectly. Thus, the affected person is confronted
with disclosure dilemmas between privacy, protection, and family
responsibilities (Rehmann-Sutter and Müller, 2009).
On a societal level, an increasing gap between progno-
sis/diagnosis and treatment can be accompanied by stigmati-
zation. This can lead to the classification of pre-symptomatic
risk-bearers, overburden them with responsibilities, and result
in their medicalization. It can also promote their discrimination
(e.g., with regard to legal status, job positions, or access to health
insurance) and commercial exploitation, e.g., through dubious
direct-to-consumer testing (Garand et al., 2009).
RECOMMENDATIONS
In dealing with predictive information, highest professional and
legal standards should be observed to protect subjects from psy-
chological distress, moral dilemmas, and social stigmatization.
This information should be used to empower affected persons
and optimize their treatment and care. Attempts to exclude them
from social participation, healthcare, or other resources must
be inhibited. Professional guidelines should be based on more
empirical, cross-cultural studies on how lay people actually deal
with LOAD risk prediction.
In a future scenario of clinical implementation of research
results, the subjects would have to be informed in advance
about all relevant possible research outcomes and their potential
implications. Their right not to know would have to be respected
(e.g., by offering an option to waive claims to be informed). How-
ever, this presents practical and ethical challenges for clinical drug
trials. Subjects would need to agree before entering the study that
they would find out their biomarker status as it may be unethical
to expose participants who do not express the targeted biomarkers
to drugs. If information were disclosed, professional counseling
would have to be provided. This should include a critical revision
of the information’s reliability, significance, and implications
for family members in order to prevent rash and inconsiderate
reactions such as pre-emptive suicides. Furthermore, practical
coping strategies and concrete problem solutions have to be
delineated. To avoid stigmatization and discrimination, restrictive
standards of confidentiality and data protection for any biomarker
test including imaging techniques would be needed. Professional
practice should take into account cultural diversity in dealing
with such information. Given the globally diverse population and
differences in legal systems, attempts are needed to foster a dialog
between science and law. In countries with low levels of informed
consent, counseling, or data protection, the scientific community
should promote high standards for clinical application. Finally,
scientists and policy makers investing in profit seeking biomedical
industries gaining from this research should avoid conflicts of
interest. Legal regulations are needed to preclude an unhampered
market of direct-to-consumer testing without sufficient evidence-
base or adequate supervision and counseling.
KEY QUESTIONS FOR FURTHER DEBATES AND RESEARCH
• How can ethical and clinical guidelines be respectful and sen-
sitive to diverse ethnic populations having often very different
understandings of family hierarchy, gender, and age norms?
• How can international consensus about data protection and
anti-stigmatization strategies be ensured (e.g., by international
associations)?
• How do we gain a minimum international ethics standard
for research to ensure ethically acceptable transnational coop-
eration and to avoid “ethics dumping” (i.e., outsourcing of
research into countries with lowest ethics standards or missing
control)?
EXPLORING DIVERSITY AND PROMOTING PUBLIC DIALOG
RATIONALE
While the neuroscience community is increasingly global-
ized, cross-national comparison reveals significant differences in
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images, practices, and policies regarding LOAD. Some national
policies emphasize individual suffering and public health burden,
others dignity, quality of life of affected persons, and societal sol-
idarity. Correspondingly, the focus of public discourses, interest
group strategies, and governmental policies can be on supporting
biomarker research or rather on providing adequate care for
patients in advanced stages. Diversity presents a practical and eco-
nomic challenge in dealing with research subjects from different
cultural backgrounds. At the same time, it constitutes a resource
for problem solving of complex human issues (Illes et al., 2007).
RECOMMENDATIONS
Since biomarker research still is in an early phase, it is a critical
point in time to envision the spectrum of implications for dealing
with LOAD. An intensified dialog between neuroscience, social
sciences, and humanities will increase the understanding of
the diversity and intersectionality (cross-influences of cultural
categories such as gender, class, religion) of cultural attitudes
towards LOAD and healthcare. Researchers and clinicians should
be careful not to impute their own attitudes without critical
consideration. Deliberative participatory processes in setting
research and healthcare policy priorities should be strengthened
to include the different perspectives and to benefit from the
abundance of approaches.
The involvement of those affected is a constitutive feature
of modern science governance that recognizes the right to self-
determination but also aims at empowering patients and their
families to take a more active role in shaping science (Schicktanz
et al., 2012). Patient associations are important mediators, but
a balanced plurality of advocacy groups should be included in
order to avoid a one-sided perspective (e.g., by over-representing
or neglecting either patients or their care-givers). Overall, framing
dementia only as a threat to social and healthcare systems should
be avoided, since this increases the stigmatization of patients and
their families. Further research into causes, prevention, and treat-
ment of LOAD, as well as adequate and respectful care for those
affected, are necessary. Both constitute morally justified and valu-
able concerns that should not be pitted against each other. More
national and international scientific societies should function as
mediators and dialog platforms to foster an interdisciplinary and
socially engaged discourse on the aims of LOAD research.
KEY QUESTIONS FOR FURTHER DEBATES AND RESEARCH
• How can we organize public deliberation that adequately
involves the perspectives of those already affected by LOAD?
• How can we foster a dialog between various experts from
bioscience, clinical care, social gerontology, ethics, and public
health research in each country?
• How can the dominance of one-sided negative images and
metaphors of dementia (e.g., “threat”, “epidemic”, “loss of self ”,
“public burden”, “living death”) be overcome?
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